Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects : A phase 1, single-centre, randomized, double-blind, dose escalation study
© 2024 John Wiley & Sons Ltd..
AIM: Novel long-acting drugs for type 2 diabetes mellitus may optimize patient compliance and glycaemic control. Exendin-4-IgG4-Fc (E4F4) is a long-acting glucagon-like peptide-1 receptor agonist. This first-in-human study investigated the safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of a single subcutaneous injection of E4F4 in healthy subjects.
METHODS: This single-centre, randomized, double-blind, placebo-controlled phase 1 clinical trial included 96 subjects in 10 sequential cohorts that were provided successively higher doses of E4F4 (0.45, 0.9, 1.8, 3.15, 4.5, 6.3, 8.1, 10.35, 12.6 and 14.85 mg) or placebo (ChinaDrugTrials.org.cn: ChiCTR2100049732). The primary endpoint was safety and tolerability of E4F4. Secondary endpoints were pharmacokinetic, pharmacodynamic and immunogenicity profiles of E4F4. Safety data to day 15 after the final subject in a cohort had been dosed were reviewed before commencing the next dose level.
RESULTS: E4F4 was safe and well tolerated among healthy Chinese participants in this study. There was no obvious dose-dependent relationship between frequency, severity or causality of treatment-emergent adverse events. Cmax and area under the curve of E4F4 were dose proportional over the 0.45-14.85 mg dose range. Median Tmax and t1/2 ranged from 146 to 210 h and 199 to 252 h, respectively, across E4F4 doses, with no dose-dependent trends. For the intravenous glucose tolerance test, area under the curve of glucose in plasma from time 0 to 180 min showed a dose-response relationship in the 1.8-10.35 mg dose range, with an increased response at the higher doses.
CONCLUSION: E4F4 exhibited an acceptable safety profile and linear pharmacokinetics in healthy subjects. The recommended phase 2 dose is 4.5-10.35 mg once every 2 weeks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Diabetes, obesity & metabolism - 26(2024), 4 vom: 29. März, Seite 1395-1406 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Gui-Ling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9P1872D4OL |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dom.15441 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367774739 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367774739 | ||
| 003 | DE-627 | ||
| 005 | 20240314235000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.15441 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM367774739 | ||
| 035 | |a (NLM)38287130 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Gui-Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects |b A phase 1, single-centre, randomized, double-blind, dose escalation study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 John Wiley & Sons Ltd. | ||
| 520 | |a AIM: Novel long-acting drugs for type 2 diabetes mellitus may optimize patient compliance and glycaemic control. Exendin-4-IgG4-Fc (E4F4) is a long-acting glucagon-like peptide-1 receptor agonist. This first-in-human study investigated the safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of a single subcutaneous injection of E4F4 in healthy subjects | ||
| 520 | |a METHODS: This single-centre, randomized, double-blind, placebo-controlled phase 1 clinical trial included 96 subjects in 10 sequential cohorts that were provided successively higher doses of E4F4 (0.45, 0.9, 1.8, 3.15, 4.5, 6.3, 8.1, 10.35, 12.6 and 14.85 mg) or placebo (ChinaDrugTrials.org.cn: ChiCTR2100049732). The primary endpoint was safety and tolerability of E4F4. Secondary endpoints were pharmacokinetic, pharmacodynamic and immunogenicity profiles of E4F4. Safety data to day 15 after the final subject in a cohort had been dosed were reviewed before commencing the next dose level | ||
| 520 | |a RESULTS: E4F4 was safe and well tolerated among healthy Chinese participants in this study. There was no obvious dose-dependent relationship between frequency, severity or causality of treatment-emergent adverse events. Cmax and area under the curve of E4F4 were dose proportional over the 0.45-14.85 mg dose range. Median Tmax and t1/2 ranged from 146 to 210 h and 199 to 252 h, respectively, across E4F4 doses, with no dose-dependent trends. For the intravenous glucose tolerance test, area under the curve of glucose in plasma from time 0 to 180 min showed a dose-response relationship in the 1.8-10.35 mg dose range, with an increased response at the higher doses | ||
| 520 | |a CONCLUSION: E4F4 exhibited an acceptable safety profile and linear pharmacokinetics in healthy subjects. The recommended phase 2 dose is 4.5-10.35 mg once every 2 weeks | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a E4F4 | |
| 650 | 4 | |a GLP-1 RA | |
| 650 | 4 | |a phase I clinical trial | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Exenatide |2 NLM | |
| 650 | 7 | |a 9P1872D4OL |2 NLM | |
| 700 | 1 | |a Liu, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xue-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Kai-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yun-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Cong-Gao |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Ting-Han |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yu-Bao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yao-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Tong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Xiang-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Jing-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Si-Xiu |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yong-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hong-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Yan-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Yaru |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Zhen-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yun-Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Shou, Zhang-Fei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 26(2024), 4 vom: 29. März, Seite 1395-1406 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:4 |g day:29 |g month:03 |g pages:1395-1406 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.15441 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 4 |b 29 |c 03 |h 1395-1406 | ||